{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109146","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.824522+00:00","generated_at":"2026-05-16T22:24:15.702823+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven","bullets":["YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).","Non-GAAP net income from ops $2.3M (vs -$2.9M); GAAP net income $3.6M (includes $6.5M tax benefit).","Phase 3 CYPRESS of ampreloxetine (MSA-nOH): open-label done; topline data Q1 2026.","Cash $333M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.","Company achieves non-GAAP breakeven, underscoring financial discipline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109146","json":"https://secwatch.observer/filing/0001104659-25-109146.json","markdown":"https://secwatch.observer/filing/0001104659-25-109146.md","text":"https://secwatch.observer/filing/0001104659-25-109146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925109146/0001104659-25-109146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925109146/tm2530676d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:24:15.702823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}